These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 3351005)

  • 21. Current Psychopharmacology of Obsessive-Compulsive Spectrum Disorders.
    Del Casale A; Kotzalidis GD; Rapinesi C; Girardi P
    Curr Neuropharmacol; 2019; 17(8):668-671. PubMed ID: 31393238
    [No Abstract]   [Full Text] [Related]  

  • 22. Oxytocin and vasopressin in obsessive-compulsive disorder.
    Salzberg AD; Swedo SE
    Am J Psychiatry; 1992 May; 149(5):713-4. PubMed ID: 1575271
    [No Abstract]   [Full Text] [Related]  

  • 23. Silymarin for the treatment of obsessive-compulsive disorders in dermatology.
    França K; Lotti T
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28338269
    [No Abstract]   [Full Text] [Related]  

  • 24. Tardive oculogyria.
    Friedman EH
    Neurology; 1990 Apr; 40(4):728. PubMed ID: 2320264
    [No Abstract]   [Full Text] [Related]  

  • 25. Potential antidopaminergic effects of serotonin reuptake inhibitors.
    Kim SW; Dysken MW
    J Clin Psychiatry; 1991 Jan; 52(1):42. PubMed ID: 1988420
    [No Abstract]   [Full Text] [Related]  

  • 26. Desensitization of terminal 5-HT autoreceptors by 5-HT reuptake blockers.
    de Montigny C; Blier P
    Arch Gen Psychiatry; 1991 May; 48(5):483-4. PubMed ID: 2021304
    [No Abstract]   [Full Text] [Related]  

  • 27. Psychopharmacology of drugs effective in obsessive-compulsive disorder.
    Taniguchi G
    J Clin Psychopharmacol; 1988 Feb; 8(1):71. PubMed ID: 3351005
    [No Abstract]   [Full Text] [Related]  

  • 28. The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis.
    McDougle CJ; Goodman WK; Leckman JF; Price LH
    Psychiatr Clin North Am; 1993 Dec; 16(4):749-66. PubMed ID: 8309811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Monoamine oxidase inhibitors in the treatment of obsessive disorders. Two case reports and review of the literature].
    Erfurth A; Schmauss M
    Nervenarzt; 1993 Jan; 64(1):70-2. PubMed ID: 8437650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders.
    Kamijima K; Aoki M
    Expert Rev Neurother; 2006 Jul; 6(7):945-56. PubMed ID: 16831110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic applications and mechanisms of action of monoamine oxidase inhibitor and heterocyclic antidepressant drugs.
    Goodman WK; Charney DS
    J Clin Psychiatry; 1985 Oct; 46(10 Pt 2):6-24. PubMed ID: 3900056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obsessive-compulsive disorder and its treatment with serotonin-selective agents.
    Murphy DL; Pigott TA
    Prog Clin Biol Res; 1990; 361():179-201. PubMed ID: 2290841
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.